We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+25.88%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$7.99B
AUM Growth
+$1.36B
Cap. Flow
+$220M
Cap. Flow %
2.75%
Top 10 Hldgs %
82.62%
Holding
149
New
30
Increased
33
Reduced
21
Closed
40

Top Buys

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$40.6M
2
TSRO
TESARO, Inc.
TSRO
+$32.2M
3
BPMC
Blueprint Medicines
BPMC
+$30.2M
4
NKTR icon
Nektar Therapeutics
NKTR
+$25.8M
5
FOLD
Amicus Therapeutics
FOLD
+$22.8M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$21.1M
2
INCY icon
Incyte
INCY
+$18M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$8.37M
4
CLVS
Clovis Oncology, Inc.
CLVS
+$5.83M
5
ALDR
Alder Biopharmaceuticals
ALDR
+$5.72M

Sector Composition

Rank Sector Weight
1 Consumer Staples 43.57%
2 Consumer Discretionary 23.48%
3 Healthcare 17.87%
4 Miscellaneous 14.88%
5 Communication Services 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BUFF
1
DELISTED
Blue Buffalo Pet Products, Inc
BUFF
$3.48B 43.57%
87,460,875
– –
WW
2
DELISTED
WW International
WW
$1.88B 23.48%
29,443,300
– –
LXRX icon
3
Lexicon Pharmaceuticals
LXRX
$881M
$499M 6.25%
58,274,650
– –
SPY icon
4
CALL
State Street SPDR S&P 500 ETF Trust
SPY
$803B
$132M 1.65%
+500,000
New +$136M
BAC icon
5
CALL
Bank of America
BAC
$416B
$130M 1.63%
4,350,000
-1,450,000
-25% -$45.5M
GM icon
6
CALL
General Motors
GM
$76.5B
$127M 1.59%
+3,500,000
New +$142M
ONC
7
BeOne Medicines Ltd
ONC
$40B
$101M 1.26%
600,000
+300,000
+100% +$40.6M
IBM icon
8
CALL
IBM
IBM
$235B
$92.1M 1.15%
627,600
-209,200
-25% -$31.7M
GS icon
9
CALL
Goldman Sachs
GS
$288B
$88.2M 1.1%
350,000
+150,000
+75% +$39.1M
XOM icon
10
CALL
ExxonMobil
XOM
$679B
$74.6M 0.93%
+1,000,000
New +$79.9M
NKTR icon
11
Nektar Therapeutics
NKTR
$2.34B
$74.4M 0.93%
46,667
+20,000
+75% +$25.8M
ALNY icon
12
Alnylam Pharmaceuticals
ALNY
$33.5B
$71.5M 0.89%
600,000
+150,000
+33% +$19.3M
WFC icon
13
CALL
Wells Fargo
WFC
$268B
$68.1M 0.85%
1,300,000
-200,000
-13% -$11.9M
CELG
14
CALL
DELISTED
Celgene Corp
CELG
$58M 0.73%
650,000
+500,000
+333% +$48M
CVX icon
15
CALL
Chevron
CVX
$416B
$57M 0.71%
+500,000
New +$59.8M
BMY icon
16
CALL
Bristol-Myers Squibb
BMY
$131B
$56.9M 0.71%
900,000
– –
ATRA icon
17
Atara Biotherapeutics
ATRA
$92.8M
$48.8M 0.61%
50,000
+10,000
+25% +$9.11M
INCY icon
18
CALL
Incyte
INCY
$24.8B
$45.8M 0.57%
550,000
+300,000
+120% +$27M
XBI icon
19
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.6B
$43.9M 0.55%
500,000
+100,000
+25% +$9.13M
BPMC
20
DELISTED
Blueprint Medicines
BPMC
$41.3M 0.52%
450,000
+350,000
+350% +$30.2M
AGIO icon
21
Agios Pharmaceuticals
AGIO
$1.98B
$40.9M 0.51%
500,000
– –
FOLD
22
DELISTED
Amicus Therapeutics
FOLD
$37.6M 0.47%
2,500,000
+1,500,000
+150% +$22.8M
TSRO
23
DELISTED
TESARO, Inc.
TSRO
$34.3M 0.43%
600,000
+500,000
+500% +$32.2M
XLRN
24
DELISTED
Acceleron Pharma
XLRN
$33.2M 0.42%
850,000
+100,000
+13% +$4.25M
ARRY
25
DELISTED
Array Biopharma Inc
ARRY
$32.6M 0.41%
2,000,000
+500,000
+33% +$8.01M
1
2 3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q1 2018 Portfolio in Review

As of Q1 2018, Artal Group held 149 positions worth $7.99B, up 21% from $6.63B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Artal Group's Q1 2018 filing shows 30 new, 33 increased, 21 reduced and 40 closed positions. Its largest new stake was Kyntra Bio: 10,000 shares worth $11.6M. The largest sale was Neurocrine Biosciences, an estimated $21.1M.

By sector, the portfolio is most concentrated in Consumer Staples at 44% of assets, up from 43% a quarter earlier, followed by Consumer Discretionary and Healthcare.

  • Artal Group's largest Q1 2018 buy was Kyntra Bio: 10,000 shares worth $11.6M.
  • Artal Group added most to BeOne Medicines Ltd in Q1 2018, an estimated $40.6M increase.
  • Artal Group's biggest Q1 2018 reduction was Incyte, cutting an estimated $18M.
  • Artal Group fully exited Neurocrine Biosciences in Q1 2018, selling an estimated $21.1M.
  • Artal Group's ten largest holdings make up 83% of its $7.99B portfolio in Q1 2018.
  • Artal Group opened 30 new positions and closed 40 in Q1 2018.
  • Artal Group's portfolio value rose 21% quarter-over-quarter to $7.99B.

Based on Artal Group's 13F filing for Q1 2018, filed 10 May 2018.